Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 1
Submit an article Journal homepage
147
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas

Tamer Othmana University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
,
Benjamin N. Moskoffa University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
,
Naseem Esteghamata University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
,
Rasmus T. Hoegb Internal Medicine, Hematology and Oncology Department, University of California Davis School of Medicine, Sacramento, CA, USA
,
Aaron S. Rosenberga University of California Davis Comprehensive Cancer Center, Sacramento, CA, USAORCID Iconhttps://orcid.org/0000-0003-0714-734X
ORCID Icon,
Brian A. Jonasb Internal Medicine, Hematology and Oncology Department, University of California Davis School of Medicine, Sacramento, CA, USAORCID Iconhttps://orcid.org/0000-0002-4921-5809
ORCID Icon,
Mehrdad Abedib Internal Medicine, Hematology and Oncology Department, University of California Davis School of Medicine, Sacramento, CA, USA
,
Carol Richmana University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
&
Joseph M. Tuscanoa University of California Davis Comprehensive Cancer Center, Sacramento, CA, USACorrespondence[email protected]
 show all
Pages 231-234 | Received 23 Jun 2021, Accepted 21 Aug 2021, Published online: 06 Sep 2021

References

  • Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23(9):1993–2003.
  • Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530–1538.
  • McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–3400.
  • Pillai AB, George TI, Dutt S, et al. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4 + CD25 + Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood. 2009;113(18):4458–4467.
  • Mavers M, Maas-Bauer K, Negrin RS. Invariant natural killer T cells as suppressors of graft-versus-Host disease in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2017;8(900):900.
  • Spinner MA, Kennedy VE, Tamaresis JS, et al. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Adv. 2019;3(16):2454–2464.
  • Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114(5):1099–1109.
  • Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
  • Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3):250–259.
  • Cardenas ML, Abedi M, Romo C, et al. The addition of ibritumomab tiuxetan (IT) to the ATG/TLI preparative regimen is safe and may enhance Post-Transplant response and outcomes for patients with relapsed or refractory B cell Non-Hodgkin lymphomas. Blood. 2019;134(Supplement_1):3334–3334.
  • Baron F, Zachée P, Maertens J, et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol. 2015;8:4.
  • Hannon M, Beguin Y, Ehx G, et al. Immune recovery after allogeneic hematopoietic stem cell transplantation following Flu-TBI versus TLI-ATG conditioning. Clin Cancer Res. 2015;21(14):3131–3139.
  • Veltri L, Regier M, Cumpston A, et al. Incidence and pattern of graft-versus-Host disease in patients undergoing allogeneic transplantation after nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin. Bone Marrow Res. 2013;2013:414959.
  • Tamari R, Devlin S, Goldberg JD, et al. Infections are the major cause of non relapse mortality (NRM) after T cell depleted (TCD) allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome. Biology of Blood and Marrow Transplantation. 2014;20(2):S44.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.